Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, Cooley S, Miller JS, Klimkowska M, Schaffer M, Watz E, Wikström K, Blomberg P, Wahlin BE, Palma M, Hansson L, Ljungman P, Hellström-Lindberg E, Ljunggren HG, Malmberg KJ. Björklund AT, et al. Among authors: palma m. Clin Cancer Res. 2018 Apr 15;24(8):1834-1844. doi: 10.1158/1078-0432.CCR-17-3196. Epub 2018 Feb 14. Clin Cancer Res. 2018. PMID: 29444931 Clinical Trial.
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.
Palma M, Adamson L, Hansson L, Kokhaei P, Rezvany R, Mellstedt H, Osterborg A, Choudhury A. Palma M, et al. Cancer Immunol Immunother. 2008 Nov;57(11):1705-10. doi: 10.1007/s00262-008-0561-y. Epub 2008 Jul 29. Cancer Immunol Immunother. 2008. PMID: 18663443 Free PMC article. Review.
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.
Palma M, Hansson L, Choudhury A, Näsman-Glaser B, Eriksson I, Adamson L, Rossmann E, Widén K, Horváth R, Kokhaei P, Vertuani S, Mellstedt H, Osterborg A. Palma M, et al. Cancer Immunol Immunother. 2012 Jun;61(6):865-79. doi: 10.1007/s00262-011-1149-5. Epub 2011 Nov 16. Cancer Immunol Immunother. 2012. PMID: 22086161 Free PMC article.
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J. Winqvist M, et al. Among authors: palma m. Cancer Immunol Immunother. 2017 Jan;66(1):91-102. doi: 10.1007/s00262-016-1922-6. Epub 2016 Nov 4. Cancer Immunol Immunother. 2017. PMID: 27815572 Free PMC article. Clinical Trial.
1,599 results